IGF1R and glioblastoma: For directly targeting key components of the oncogenesis, strategies have been tested against other solid cancers like glioblastoma in the NCT01550523 trial, where autologous tumor cell-derived EVs carrying antisense oligodeoxynucleotides targeting IGF-1R, overexpressed in most glioblastomas, were evaluated, expecting significant repression of IGF-1R translation and consequent tumor growth arrest [160,161].